ft 21 jul 92 technolog fresh water gene pool explor role genet drug play cure diseas sourc entir new gener drug act directli human gene like transform pharmaceut industri next two decad genet drug sale could worth ten billion dollar year within 20 year almost everi drug today act protein chemic work live creatur virus peopl rapid expans genet knowledg made possibl target drug origin caus troubl gene tell cell exactli protein make alreadi scientist know sequenc function thousand gene human anim plant micro organ expect within 15 year discov estim 100 000 gene provid blueprint everi human genet drug aim either defect gene patient cell infecti organ virus promis cure diseas hard treat exist medicin exquisit specif use favourit phrase biotechnologist avoid side effect today protein base drug two broad categori genet drug begin clinic trial gene therapi involv insert new gene cell produc therapeut protein bodi anti sens therapi code block opposit process switch gene stop make harm protein common view biotechnolog industri last year anti sens commerci potenti gene therapi least medium term principl simpler process specif gene switch molecul small enough made orthodox chemic synthesi gene therapi hand requir whole new gene thousand time larger anti sens drug made biotechnolog also appear immens problem deliv new gene cell need get work last month anti sens research continu make progress isi pharmaceut california start clinic trial anti sens drug treat human papilloma viru caus genit wart cervic cancer sever us compani specialis anti sens technolog includ genta gilead hybridon targetech develop drug aim wide varieti diseas target includ viral infect hepat b aid herp leukaemia cancer inflammatori disord gene therapi move forward even faster scientif commerci front view emerg pharmaceut industri eventu import anti sens technolog research us nation institut health nih carri first human gene therapi trial septemb 1990 four year old girl kept apart children one defect gene immun system meant natur protect infect everi month sinc receiv transfus billion blood cell copi correct gene ad treatment repeat genet engin cell gradual die immun defenc strong enough attend school normal success led flood propos gene therapi experi us clinic develop genet medicin well ahead europ japan american regul alreadi approv 20 clinic trial anti sens start compani rush exploit technolog therapi inc gti base maryland near nih enjoy close relationship pioneer gene therapi research other includ somatix therapi viagen target genet tran karyot therapi vical rang treatment propos gene therapi even wider anti sens fall two main categori replac faulti miss human gene candid treatment near futur includ inherit singl gene disord cystic fibrosi haemophilia eventu may possibl treat combin genet fault heart diseas degen brain diseas valuabl target give patient cell abil produc therapeut protein normal present bodi potenti treat mani form cancer even rapid progress last year howev research still overcom sever technic problem gene therapi anti sens becom mass market treatment import develop better way enabl genet therapeut reach cell need first gener anti sens drug design reach difficult site insid bodi genta appli bone marrow cell remov temporarili bodi switch cancer caus gene leukaemia isi target viral gene herp papilloma infect near skin earli gene therapi trial use genet engin virus insert new gene patient cell although viru disabl prevent caus harm research cannot rule slight risk might stimul latent infect even trigger cancer new deliveri system prospect categori genet treatment anti sens drug link chemic make permeat cell effect non viral vector develop gene therapi recent establish pharmaceut giant left gene base medicin academ scientist biotechnolog start up scrambl catch start research hous form allianc specialist biotech compani isi exampl partnership ciba geigi switzerland eisai japan rhone poulenc franc gilead competitor collabor research agreement glaxo uk gti work sandoz switzerland shown interest gene therapi larg pharmaceut compani research talk total sale genet drug run ten billion dollar within 20 year though estim highli specul robertson stephen amp co californian invest analyst say us gene therapi market three cancer renal ovarian melanoma potenti worth dollar 1 2bn year base cost dollar 15 000 per patient seem expens may accept price treatment save patient life also ten thousand dollar hospit fee